PegBio (Ticker: 2565 HK) is a biotechnology company focused on discovering and developing innovative peptide and small molecule drugs for chronic diseases, particularly metabolic disorders such as type 2 diabetes and obesity. Its core product, PB-119, a GLP-1 receptor agonist, has had its New Drug Application accepted in China. PegBio plans an H-share listing on the Hong Kong Stock Exchange Main Board on May 27, 2025. The company is offering approximately 19.285 million shares at HKD15.6 per share, aiming to raise around HKD300.85 million (approximately USD 38.47 million). Listing under HKEX rules for pre-revenue biotech companies, Yizekangrui Medical (HK) Limited has reportedly committed HKD198 million as a cornerstone investor.